Third-Line Chemotherapy and Novel Agents for Metastatic Germ Cell Tumors

Hematology/Oncology Clinics of North America

Volumn 25, Issue 3, 2011, Pages 577-591

  Veenstra, Christine M ^a   Vaughn, David J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cisplatin; Germ cell; Neoplasm; Refractory; Testicular

Indexed keywords

BEVACIZUMAB; BLEOMYCIN; CISPLATIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; NEDAPLATIN; OXALIPLATIN; PACLITAXEL;

CANCER CHEMOTHERAPY; CANCER RELAPSE; DRUG RESISTANCE; GERM CELL TUMOR; HUMAN; METASTASIS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; TESTIS TERATOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GERM CELL AND EMBRYONAL; TESTICULAR NEOPLASMS;

EID: 79955826707     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2011.03.005     Document Type: Review

References (86)

1. Porcu P., Bhatia S., Sharma M., et al. Results of treatment after relapse from high-dose chemotherapy in germ cell tumors. J Clin Oncol 2000, 18(6):1181-1186.
2. Kollmannsberger C., Schleucher N., Rick O., et al. Analysis of salvage treatments for germ cell cancer patients who have relapsed after primary high-dose chemotherapy plus autologous stem cell support. Eur J Cancer 2003, 39(6):775-782.
3. Einhorn L.H. Treatment of testicular cancer: a new and improved model. J Clin Oncol 1990, 8(11):1777-1781.
4. Kollmannsberger C., Nichols C., Bokemeyer C. Recent advances in management of patients with platinum-refractory testicular germ cell tumors. Cancer 2006, 106(6):1217-1226.
5. Kollmannsberger C., Honecker F., Bokemeyer C. Pharmacotherapy of relapsed metastatic testicular cancer. Expert Opin Pharmacother 2008, 9(13):2259-2272.
6. Piulats J.M., Jimenez L., Garcia del Muro X., et al. Molecular mechanisms behind the resistance of cisplatin in germ cell tumours. Clin Transl Oncol 2009, 11(12):780-786.
7. Masters J.R., Koberle B. Curing metastatic cancer: lessons from testicular germ-cell tumours. Nat Rev Cancer 2003, 3(7):517-525.
8. Ishida S., Lee J., Thiele D.J., et al. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci U S A 2002, 99(22):14298-14302.
9. Holzer A.K., Howell S.B. The internalization and degradation of human copper transporter 1 following cisplatin exposure. Cancer Res 2006, 66(22):10944-10952.
10. Borst P., Evers R., Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000, 92(16):1295-1302.
11. Scheffer G.L., Kool M., Hejin M., et al. Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies. Cancer Res 2000, 60(18):5269-5277.
12. Scheffer G.L., Schroeijers A.B., Izquierdo M.A., et al. Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer. Curr Opin Oncol 2000, 12(6):550-556.
13. Masters J.R., Thomas R., Hall A.G., et al. Sensitivity of testis tumour cells to chemotherapeutic drugs: role of detoxifying pathways. Eur J Cancer 1996, 32A(7):1248-1253.
14. Sark M.W., Timmer-Bosscha H., Meijer C., et al. Cellular basis for differential sensitivity to cisplatin in human germ cell tumour and colon carcinoma cell lines. Br J Cancer 1995, 71(4):684-690.
15. Koberle B., Grimaldi K.A., Sunters A., et al. DNA repair capacity and cisplatin sensitivity of human testis tumour cells. Int J Cancer 1997, 70(5):551-555.
16. Koberle B., Masters J.R., Hartley J.A., et al. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr Biol 1999, 9(5):273-276.
17. Honecker F., Mayer F., Stoop H., et al. Xeroderma pigmentosum group a protein and chemotherapy resistance in human germ cell tumors. Lab Invest 2003, 83(10):1489-1495.
18. Zamble D.B., Mu D., Reardon J.T., et al. Repair of cisplatin-DNA adducts by the mammalian excision nuclease. Biochemistry 1996, 35(31):10004-10013.
19. Mayer F., Gillis A.J., Dinjens W., et al. Microsatellite instability of germ cell tumors is associated with resistance to systemic treatment. Cancer Res 2002, 62(10):2758-2760.
20. Honecker F., Wermann H., Mayer F., et al. Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors. J Clin Oncol 2009, 27(13):2129-2136.
21. Lutzker S.G., Mathew R., Taller D.R. A p53 dose-response relationship for sensitivity to DNA damage in isogenic teratocarcinoma cells. Oncogene 2001, 20(23):2982-2986.
22. Kersemaekers A.M., Mayer F., Molier M., et al. Role of P53 and MDM2 in treatment response of human germ cell tumors. J Clin Oncol 2002, 20(6):1551-1561.
23. Burger H., Nooter K., Boersma A.W., et al. Distinct p53-independent apoptotic cell death signalling pathways in testicular germ cell tumour cell lines. Int J Cancer 1999, 81(4):620-628.
24. Mayer F., Stoop H., L Scheffer G., et al. Molecular determinants of treatment response in human germ cell tumors. Clin Cancer Res 2003, 9(2):767-773.
25. Fitzharris B.M., Kaye S.B., Saverymuttu S., et al. VP16-213 as a single agent in advanced testicular tumors. Eur J Cancer 1980, 16(9):1193-1197.
26. Loehrer P.J. Etoposide therapy for testicular cancer. Cancer 1991, 67(Suppl 1):220-224.
27. Miller J.C., Einhorn L.H. Phase II study of daily oral etoposide in refractory germ cell tumors. Semin Oncol 1990, 17(1 Suppl 2):36-39.
28. Scheulen M.E., Niederle N., Bremer K., et al. Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna: results of a clinical phase II-study with 151 patients. Cancer Treat Rev 1983, 10(Suppl A):93-101.
29. Wheeler B.M., Loehrer P.J., Williams S.D., et al. Ifosfamide in refractory male germ cell tumors. J Clin Oncol 1986, 4(1):28-34.
30. Einhorn L.H. Ifosfamide in germ cell tumors. Oncology 2003, 65(Suppl 2):73-75.
31. Motzer R.J., Bajorin D.F., Schwartz L.H., et al. Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol 1994, 12(11):2277-2283.
32. Bokemeyer C., Beyer J., Metzner B., et al. Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann Oncol 1996, 7(1):31-34.
33. Bokemeyer C., Schmoll H.J., Natt F., et al. Preliminary results of a phase I/II trial of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. J Cancer Res Clin Oncol 1994, 120(12):754-757.
34. Nazario A., Amato R., Hutchinson L., et al. Paclitaxel in extensively pretreated nonseminomatous germ cell tumors. Urol Oncol 1995, 1(5):184-187.
35. Sandler A.B., Cristou A., Fox S., et al. A phase II trial of paclitaxel in refractory germ cell tumors. Cancer 1998, 82(7):1381-1386.
36. Berruti A., Saini A., Gorzegno G., et al. Durable complete remission after weekly docetaxel administration in a patient with mediastinal non-seminomatous germ-cell tumor refractory to cisplatin-based chemotherapy. Ann Oncol 2003, 14(10):1589-1590.
37. Bokemeyer C., Gerl A., Schoffski P., et al. Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer. J Clin Oncol 1999, 17(2):512-516.
38. Einhorn L.H., Stender M.J., Williams S.D. Phase II trial of gemcitabine in refractory germ cell tumors. J Clin Oncol 1999, 17(2):509-511.
39. Dunn T.A., Schmoll H.J., Grunwald V., et al. Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines. Invest New Drugs 1997, 15(2):109-114.
40. Kollmannsberger C., Rick O., Derigs H.G., et al. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol 2002, 20(8):2031-2037.
41. Fizazi K., Culine S., Chen I. Oxaliplatin in non-seminomatous germ-cell tumors. Ann Oncol 2004, 15(8):1295.
42. Hinton S., Catalano P., Einhorn L.H., et al. Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2002, 20(7):1859-1863.
43. Einhorn L.H., Brames M.J., Juliar B., et al. Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant. J Clin Oncol 2007, 25(5):513-516.
44. Kollmannsberger C., Beyer J., Liersch R., et al. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol 2004, 22(1):108-114.
45. Pectasides D., Pectasides M., Farmakis D., et al. Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study. Ann Oncol 2004, 15(3):493-497.
46. De Giorgi U., Rosti G., Aieta M., et al. Phase II study of oxaliplatin and gemcitabine salvage chemotherapy in patients with cisplatin-refractory nonseminomatous germ cell tumor. Eur Urol 2006, 50(5):1032-1038. [discussion: 1038-9].
47. Theodore C., Chevreau C., Yataqhene Y., et al. A phase II multicenter study of oxaliplatin in combination with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for germ-cell tumors. Ann Oncol 2008, 19(8):1465-1469.
48. Necchi A., Nicolai N., Salvioni R. Does oxaliplatin and paclitaxel combination show an activity of some extent in pretreated patients with germ-cell tumors? Reply to the article " A phase II multicenter study of oxaliplatin in combination with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for germ-cell tumors" by C. Theodore et al. (Ann Oncol 2008; doi: 10.1093/annonc/mdn122). Ann Oncol 2008, 19(8):1509.
49. Ramasubbaiah J., Brames J., Johnston E.L., et al. Phase II study of oxaliplatin (O) and bevacizumab (B) chemotherapy in refractory germ cell tumors (GCT) [abstract]. J Clin Oncol 2010, 28(15):e15054.
50. Bedano P.M., Brames M.J., Williams S.D., et al. Phase II study of cisplatin plus epirubicin salvage chemotherapy in refractory germ cell tumors. J Clin Oncol 2006, 24(34):5403-5407.
51. Kollmannsberger C., Rick O., Klaproth H., et al. Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group. Br J Cancer 2002, 87(7):729-732.
52. Miki T., Mizutani Y., Nonomura N., et al. Irinotecan plus cisplatin has substantial antitumor effect as salvage chemotherapy against germ cell tumors. Cancer 2002, 95(9):1879-1885.
53. Pectasides D., Pectasides M., Farmakis D., et al. Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor as third-line treatment in relapsed or cisplatin-refractory germ-cell tumor patients: a phase II study. Eur Urol 2004, 46(2):216-221.
54. Shamash J., Powles T., Mutsvangwa K., et al. A phase II study using a topoisomerase I-based approach in patients with multiply relapsed germ-cell tumours. Ann Oncol 2007, 18(5):925-930.
55. Nicolai N., Necchi A., Gianni L., et al. Long-term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ-cell tumours. BJU Int 2009, 104(3):340-346.
56. Bokemeyer C., Oechsle K., Honecker F., et al. Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group. Ann Oncol 2008, 19(3):448-453.
57. Oeschle K., Kollmannsberger K., Honecker F., et al. Long term outcome in patients with cisplatin-refractory or multiply relapsed germ cell tumors following treatment with gemcitabine and oxaliplatin +/- paclitaxel [abstract]. J Clin Oncol 2010, 28(Suppl 15):4585.
58. Necchi A., Nicolai N., Piva L., et al. Long-term results of a combination of paclitaxel, oxaliplatin and gemcitabine as far rescue in heavily pre-treated male germ-cell tumors (GCT) [abstract]. J Clin Oncol 2008, 26(Suppl 15):16036.
59. Logothetis C.J., Samuels M.L., Trindade A., et al. The growing teratoma syndrome. Cancer 1982, 50(8):1629-1635.
60. Andre F., Fizazi K., Culine S., et al. The growing teratoma syndrome: results of therapy and long-term follow-up of 33 patients. Eur J Cancer 2000, 36(11):1389-1394.
61. Spiess P.E., Kassouf W., Brown G.A., et al. Surgical management of growing teratoma syndrome: the M.D. Anderson cancer center experience. J Urol 2007, 177(4):1330-1334. [discussion: 1334].
62. van der Gaast A., Kok T.C., Splinter T.A. Growing teratoma syndrome successfully treated with lymphoblastoid interferon. Eur Urol 1991, 19(3):257-258.
63. Ornadel D., Wilson A., Trask C., et al. Remission of recurrent mature teratoma with interferon therapy. J R Soc Med 1995, 88(9):533P-534P.
64. Gordon M.S., Battiato L.A., Finch D., et al. Dramatic response of teratoma-associated non-germ-cell cancer with all-trans retinoic acid in a patient with nonseminomatous germ cell tumor. Am J Clin Oncol 2001, 24(3):269-271.
65. Mego M., Reckova M., Sycova-Mila Z., et al. Bevacizumab in a growing teratoma syndrome. Case report. Ann Oncol 2007, 18(5):962-963.
66. Vaughn D.J., Flaherty K., Lal P., et al. Treatment of growing teratoma syndrome. N Engl J Med 2009, 360(4):423-424.
67. Bartkova J., Lukas C., Sorensen C.S., et al. Deregulation of the RB pathway in human testicular germ cell tumours. J Pathol 2003, 200(2):149-156.
68. Donadio A.C., Motzer R.J., Bajorin D.F., et al. Chemotherapy for teratoma with malignant transformation. J Clin Oncol 2003, 21(23):4285-4291.
69. Necchi A., Colecchia M., Nicolai N., et al. Towards the definition of the best management and prognostic factors of teratoma with malignant transformation: a single-institution case series and new proposal. BJU Int 2011, 107(7):1088-1094.
70. Fukuda S., Shirahama T., Imazono Y., et al. Expression of vascular endothelial growth factor in patients with testicular germ cell tumors as an indicator of metastatic disease. Cancer 1999, 85(6):1323-1330.
71. Rick O., Braun T., Siegert W., et al. Activity of thalidomide in patients with platinum-refractory germ-cell tumours. Eur J Cancer 2006, 42(12):1775-1779.
72. Voigt W., Kegel T., Maher G., et al. Bevacizumab plus high-dose ifosfamide, etoposide and carboplatin (HD-ICE) as third-line salvage chemotherapy induced an unexpected dramatic response in highly platinum refractory germ-cell cancer. Ann Oncol 2006, 17(3):531-533.
73. Castillo-Avila W., Piulats J.M., Garcia del Muro X., et al. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors. Clin Cancer Res 2009, 15(10):3384-3395.
74. Feldman D.R., Turkula S., Ginsberg M.S., et al. Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors. Invest New Drugs 2010, 28(4):523-528.
75. Kollmannsberger C., Oeschle K., Cheng T., et al. Sunitinib in patients with multiply relapsed or cisplatin-refractory germ cell cancer: a CUOG/GTCSG cooperative phase II study [abstract]. J Clin Oncol 2010, 28(Suppl 15):4582.
76. Nitzsche B., Gloesenkamp C., Schrader M., et al. Novel compounds with antiangiogenic and antiproliferative potency for growth control of testicular germ cell tumours. Br J Cancer 2010, 103(1):18-28.
77. Tian Q., Frierson H.F., Krystal G.W., et al. Activating c-kit gene mutations in human germ cell tumors. Am J Pathol 1999, 154(6):1643-1647.
78. Madani A., Kemmer K., Sweeney C., et al. Expression of KIT and epidermal growth factor receptor in chemotherapy refractory non-seminomatous germ-cell tumors. Ann Oncol 2003, 14(6):873-880.
79. Kemmer K., Corless C.L., Fletcher J.A., et al. KIT mutations are common in testicular seminomas. Am J Pathol 2004, 164(1):305-313.
80. Pedersini R., Vattemi E., Mazzoleni G., et al. Complete response after treatment with imatinib in pretreated disseminated testicular seminoma with overexpression of c-KIT. Lancet Oncol 2007, 8(11):1039-1040.
81. Einhorn L.H., Brames M.J., Heinrich M.C., et al. Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT. Am J Clin Oncol 2006, 29(1):12-13.
82. Moroni M., Veronese S., Schiavo R., et al. Epidermal growth factor receptor expression and activation in nonseminomatous germ cell tumors. Clin Cancer Res 2001, 7(9):2770-2775.
83. Freemantle S.J., Vaseva A.V., Ewings K.E., et al. Repression of cyclin D1 as a target for germ cell tumors. Int J Oncol 2007, 30(2):333-340.
84. Kollmannsberger C., Pressler H., Mayer F., et al. Cisplatin-refractory, HER2/neu-expressing germ-cell cancer: induction of remission by the monoclonal antibody Trastuzumab. Ann Oncol 1999, 10(11):1393-1394.
85. Soule S., Baldridge L., Kirkpatrick K., et al. HER-2/neu expression in germ cell tumours. J Clin Pathol 2002, 55(9):656-658.
86. Mandoky L., Geczi L., Bodrogi I., et al. Clinical relevance of HER-2/neu expression in germ-cell testicular tumors. Anticancer Res 2004, 24(4):2219-2224.